Replies to post #95086 on Biotech Values

[DewDiligence]

1Q10 sales of BMY’s top-selling drugs:

 
             Sales (M$)  YoY Chg 
 Plavix        1700*      16% 
 Abilify        617*       5% 
 Reyataz        373       16% 
 Sustiva        335       15% 
 Avapro         314        4% 
 Baraclude      216       42% 
 Orencia        169       36% 
 Erbitux        166*       1% 
 Sprycel        131       49% 
 Ixempra         29       21% 
 Onglyza         10*      n/a 
  
 *Subject to co-marketing agreement; 
 BMY books a portion of worldwide sales. 

[DewDiligence]

BMY announces $3B buyback authorization:

http://finance.yahoo.com/news/BristolMyers-Squibb-Announces-bw-2001947623.html?x=0&.v=1

If they were to use the entire authorization to buy at or near the current share price, the share count would be reduced by about 7%.